Abstract. Epithelial cell adhesion molecule (EpCAM) is a protein involved in cell-to-cell attachment and is considered to be strictly expressed in epithelial tissues and epithelial-derived tumors. Furthermore, EpCAM has been shown to be a negative prognostic marker for several carcinomas. In this study, we performed a genomic meta-analysis of gene expression profiles housed in the Cancer Cell Line Encyclopedia to demonstrate that EpCAM mRNA is expressed at low to moderate levels in certain sarcoma cell lines. We utilized immunohistochemical staining to confirm that the EpCAM protein is expressed in a subset of angiosarcomas and leiomyosarcomas and in all the investigated osteosarcomas. Finally, we conducted a statistical analysis of clinical data to demonstrate that EpCAM protein expression is significantly and directly correlated with the degree of cytological atypia in leiomyosarcomas. In conclusion, this data suggests that, contrary to conventional beliefs, EpCAM is expressed in a subset of sarcomas and is a negative prognostic marker for leiomyosarcomas.
Introduction
Epithelial cell adhesion molecule (EpCAM) is a 40-kDa glycosylated transmembrane cell surface protein that plays an important role in Ca 2+ independent hemophilic cell-to-cell adhesion, cell signaling, migration, proliferation and differentiation (1) . EpCAM was reported to be exclusively present in epithelial tissues and is highly expressed across a large number of epithelial cancers (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Particular interest has been focused on EpCAM expression as a poor prognostic biomarker across a large number of carcinomas (2, (4) (5) (6) (8) (9) (10) (12) (13) (14) (15) .
EpCAM is expressed on carcinosarcomas, which are rare biphenotypic tumors that display characteristics of epithelial as well as sarcomatous elements (16, 17) . The expression of EpCAM is considered to be absent on purely non-epithelial tumors, such as sarcomas and hematopoietic cancers. However, a recent comprehensive analysis of EpCAM expression across human tumors clearly demonstrated that EpCAM is expressed at weak to intense levels in several soft tissue sarcomas, including angiosarcoma (25%), epitheloid sarcoma (50%), fibrosarcoma (22%) and synovial sarcoma (100%) (18) . An abstract presented at the European Society for Medical Oncology indicated that EpCAM-positive circulating cells were detectable in just under half of all the soft tissue sarcoma patients investigated, although the authors were unable to determine whether the EpCAM-positive cells were of epithelial origin due to direct tumor invasion of blood vessels from the surrounding tissue or tumor cells at the moment of mesenchymal-to-epithelial transition (19) . Moreover, induced multidrug resistance in osteosarcomas has been shown to increase the expression of cell adhesion markers, including EpCAM (20) . Despite the substantial evidence described above, whether EpCAM is actually expressed on sarcomas remains debatable. Furthermore, it has not yet been determined whether the previously reported expression of EpCAM on sarcomas is of prognostic significance, as has been reported for multiple carcinomas. In this study, we aimed to determine whether EpCAM is indeed expressed at detectable levels in a subset of sarcomas and provide evidence supporting that the steady-state protein expression level of EpCAM is statistically correlated with the degree of cytological atypia in leiomyosarcomas.
Materials and methods

Meta-analysis of EpCAM expression.
The normalized intensity values of EpCAM mRNA were evaluated using the Cancer Cell Line Encyclopedia (CCLE, www.broadinstitute. org/ccle/home). This dataset compares the mRNA expression, chromosomal copy number variation and massively parallel sequencing data from 947 diverse human cancer lines (21 Quantitation of immunohistochemistry. EpCAM immunopositivity was scored semiquantitatively for the percentage of tumor cells stained and staining intensity (0, negative; +, weak; ++, moderate; and +++, strong). For statistical analysis, scoring was converted to numerical values (0, 0; +, 1; ++, 2; and +++, 3) and the mean values ± standard error of the mean for leiomyosarcomas exhibiting mild, moderate and severe cytological atypia were calculated. Two tailed t-tests were performed to determine statistical significance, which was set at P≤0.05.
Results
Expression of EpCAM across a diverse array of cancer cell lines.
CCLE is a publicly accessible cancer genomic database jointly developed by Novartis and the Broad Institute to systematically interpret mRNA expression, chromosomal copy number variation and massively parallel sequencing data from 947 human cancer lines (21) . While these groups primarily utilized this database for predictive modeling of anticancer drug sensitivity, a plethora of genomic data awaits meta-analysis to generate and test potential hypotheses that are formulated by bioinformaticians. Utilizing the data housed in the CCLE, we investigated the steady-state mRNA expression of EpCAM across the diverse array of cancer cell lines ( Fig. 1 ). As expected, EpCAM transcripts were highly expressed in a large number of carcinomas and least expressed in hematopoietic cancers, such as lymphomas. Surprisingly, sarcomas exhibited variable degrees of expression; osteosarcomas displayed moderate levels, while Ewing's sarcoma, chondrosarcoma and mixed soft tissue sarcomas exhibited low levels of EpCAM mRNA expression.
EpCAM mRNA and protein expression in sarcomas. Given the unexpected levels of EpCAM mRNA expression in osteosarcomas based on our genomic meta-analysis, we sought to verify these findings at the protein level in three sarcoma types that our laboratory is currently investigating, namely osteosarcomas, leiomyosarcomas and angiosarcomas. We utilized immunohistochemistry to detect EpCAM protein levels in clinically evaluated human tumor sections from 6 angiosarcomas, 40 osteosarcomas and 80 leiomyosarcomas. EpCAM protein was detected at low levels in half of the angiosarcomas (Table I , Fig. 2 ) and it was detectable in all the investigated osteosarcomas, with 10% of the tumors exhibiting weak expression, 87.5% exhibiting moderate expression and only 1 tumor sample exhibiting strong EpCAM expression (Table II, Fig. 2 ). We observed mild to moderate staining for EpCAM on 62.5% of the leiomyosarcoma sections that were examined in our analysis, with 51% of the tumors exhibiting weak and 11% moderate EpCAM staining (Table III, Fig. 2 ). Collectively, these data indicate that, contrary to the established scientific belief that EpCAM expression is solely limited to tissues and tumors of epithelial origin, this 'epithelial-specific' protein is indeed expressed in a subset of sarcomas of mesenchymal origin.
Correlation of EpCAM expression with cytological atypia.
In addition to the pathological classification, we obtained clinical data on the osteosarcomas and leiomyosarcomas that were utilized in our analysis of EpCAM protein expression. These data included patient gender and age for both tumor types, tumor staging and TNM classification of the osteosarcoma samples and the degree of cytological atypia for the leiomyosarcomas. Given the established prognostic significance of EpCAM expression in human carcinomas, we sought to elucidate whether this extended into sarcomas that expressed this protein. We observed that leiomyosarcomas with moderate and severe cytological atypia exhibited a significantly higher percentage of EpCAM-positive staining compared to tumors with mild cytological atypia (Fig. 3) . While 60% of leiomyosarcomas displaying mild cytological atypia were rated as EpCAM-negative, only 29 and 20% of EpCAM-negative leiomyosarcomas displayed moderate and F  38  IA  T1N0M0  ++  M  43  IA  T1N0M0  ++  F  17  IB  T2N0M0  +++  M  41  IB  T2N0M0  ++  M  19  IB  T2N0M0  ++  F  16  IIA  T2N0M0  ++  M  41  IIA  T1N0M0  ++  F  15  IIA  T2N0M0  +  F  12  IIA  T1N0M0  ++  M  13  IIA  T1N0M0  ++  F  44  IIA  T1N0M0  ++  M  37  IIA  T1N0M0  ++  M  29  IIA  T1N0M0  ++  M  32  IIA  T1N0M0  ++  M  47  IIB  T2N0M0  +  M  38  IIB  T2N0M0  ++  M  32  IIB  T2N0M0  +  M  42  IIB  T2N0M0  ++  M  11  IIB  T2N0M0  ++  M  38  IIB  T2N0M0  ++  F  32  IIB  T2N0M0  +  M  51  IIB  T2N0M0  ++  F  14  IIB  T2N0M0  ++  F  47  IIB  T2N0M0  ++  F  14  IIB  T2N0M0  ++  F  32  IIB  T2N0M0  ++  F  14  IIB  T2N0M0  ++  M  16  IIB  T2N0M0  ++  M  18  IIB  T2N0M0  ++  M  23  IIB  T2N0M0  ++  M  60  IIB  T2N0M0  ++  M  31  IIB  T2N0M0  ++  M  30  IIB  T2N0M0  ++  F  32  IIB  T2N0M0  ++  M  64  IIB  T2N0M0  ++  M  35  IIB  T2N0M0  ++  M  21  IIB  T2N0M0  ++  M  51  IIB  T2N0M0  ++  M  44  IIB  T2N0M0  ++  M  17  IIB  T2N0M0  ++ EpCAM, epithelial cell adhesion molecule; M, male; F, female. severe cytological atypia, respectively. We utilized statistical analysis as described in the Materials and methods section to correlate EpCAM expression to each known clinical characteristic and demonstrated that EpCAM expression was significantly correlated with the degree of cytological atypia in leiomyosarcomas (EpCAM expression was calculated as follows: mild, 0.50±0.14; moderate, 0.83±0.09; and severe, 0.89±0.20; P≤0.05 for all comparisons). These data indicate that the increase in EpCAM expression is directly correlated with the increase in the degree of cytological atypia.
Discussion
EpCAM has historically been shown to be expressed across epithelial tissues, with a few exceptions (22) . Additionally, EpCAM is highly overexpressed across a wide range of carcinomas and was originally described as the dominant antigen in patients with colon carcinoma (23, 24) . The expression of this protein has been associated with poor clinical prognosis in patients with a number of carcinomas by functioning as an oncogene and suppressing CD4 + T-cell-dependent immune responses (2, 5, 25, 26) . Moreover, use of the EpCAM-specific monoclonal antibody edrecolomab and the tri-functional antibody catumaxomab in patients with metastatic cancers has demonstrated positive antitumor effects (27) (28) (29) (30) , suggesting that targeting EpCAM may prove to be efficacious against certain carcinomas.
By mining the gene expression data of various cancer cell lines deposited in the CCLE portal, we quickly noticed that, despite the common scientific belief that EpCAM is strictly expressed in tissues of epithelial origin, tumors of mesenchymal origin, such as osteosarcomas, displayed moderate expression of this gene. This prompted us to delve further into EpCAM expression to demonstrate that, of the mesenchymal tumors investigated in our analysis, all osteosarcomas and over half of the leiomyosarcomas and angiosarcomas expressed EpCAM protein at detectable levels, as determined by immunohistochemistry. Our data confirmed the previous findings by Went et al (18) , suggesting that 22-100% of sarcomas express weak to intense levels of the EpCAM protein. Given that EpCAM has been extensively reported to be a prognostic biomarker for carcinomas, we sought to determine whether the prognostic significance of this protein extends to sarcomas. Using established clinical data from our panel of osteosarcoma and leiomyosarcoma samples, we identified a direct statistical correlation between EpCAM expression and the degree of cytological atypia in leiomyosarcomas. Cytological atypia is one of the most significant prognostic factors for leiomyosarcoma (31) ; thus, similar to the results obtained for carcinomas, EpCAM expression is a negative prognostic factor for leiomyosarcomas.
This study, contrary to the current clinical perception that EpCAM is solely expressed in epithelial tissues, suggests that EpCAM mRNA and protein expression may be used as a prognostic biomarker for leiomyosarcoma severity and will potentially expand the number of cancers exhibiting susceptibility to immunotherapy against EpCAM.
